This site is intended only for Australian Healthcare Professionals




Sign In or RegisterLog Out Our medicinesTherapy areasExplore contentExplore contentEventsVideosMaterialsLet’s connectLet's ConnectContact usAsk a questionPfizer Medical InformationStay connectedSuggest a topicPharmacy HubKnowledge Hub
AboutRecommendationsDosing and AdministrationEfficacy and SafetyEfficacy ProfileSafety ProfileSupport and ResourcesEventsMaterialsVideos

ABRYSVO is also indicated for active immunisation of individuals 60 years of age and above for prevention of lower respiratory tract disease caused by RSV.1 Click here for more information. 

EVERY BREATH MATTERS.Don’t let RSV take her baby’s breath away.

Talk to your pregnant patients about maternal vaccination with ABRYSVO, and help protect infants against respiratory syncytial virus (RSV) from birth.1-2

ABRYSVO is indicated for the active immunisation of pregnant women (24-36 weeks gestation) for preventation of lower respiratory tract disease (LRTD) caused by RSV in infants (birth through 6 months of age).1

Recommendations Loading Dosing and Administration Loading Reconstitution LoadingInfants are at increased risk of hospitalisation due to RSV5

The highest number of RSV-coded hospitalisations occur in infants aged under 6 months in Australia.5

In Australia, infants are more than 12x likely to be admitted to hospital with RSV as children aged 1–4 years.5

ABRYSVO helps protect infants against RSV from birth‡1  81.8% vaccine efficacy against severe medically attended lower respiratory tract disease caused by RSV in infants from birth through 90 days of age (99.5% CI: 40.6%, 96.3%). Vaccine efficacy at 120 days (73.9 [97.58% CI 45.6, 88.8]), 150 days (70.9 [97.58% CI 44.5, 85.9]) and 180 days (69.4 [97.58% CI 44.3, 84.1]). Vaccine efficacy results met the statistical criterion for success of a CI lower bound >20% for reducing severe medically-attended LRTD due to RSV.1

ABRYSVO is indicated for:

  • Active immunisation of pregnant women (24-36 weeks gestation) for preventation of lower respiratory tract disease caused by RSV in infants (birth through 6 months of age).1
  • Active immunisation of individuals (60 years of age and above) for prevention of lower respiratory tract disease caused by RSV.1
Learn more about the ABRYSVO adult indication hereLoading
Scroll left to view table
Pregnant woman receives ABRYSVO between weeks 24 and 36 of pregnancy.1 Pregnant woman’s immune system produces antibodies, which are passed through the placenta to the foetus.1 Infant is born with maternal antibodies, which help protect against LRTD caused by RSV from birth through 6 months.2
Learn more Loading

Lorem ipsum dolor sit amet, consectetur badipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua.

Zur Produktseite Maternal Loading Zur Produktseite Ältere Erwachsene Loading Fachinformation Loading
LRTD, lower respiratory tract disease; RSV, respiratory syncytial virus.References:ABRYSVO Approved Product Information.Kampmann B, et al. N Engl J Med. 2023;388(16):1451–1464.Green LJ, et al. Obstet Gynecol. 2020;135(3):653–664.Data on file. Saravanos GL, et al. Med J Aust. 2019;210(10):447–453.

Before prescribing, please review Product Information available here.

This vaccine is subject to additional monitoring in Australia. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse events at 

PBS Information: This product is not listed on the National Immunisation Program (NIP) or the PBS

PP-A1G-AUS-0026. 03/24.
PfizerPro AccountPfizerPro Account

To access further materials, resources and receive communication about Pfizer medicines and vaccines.

Sign inRegisterAccountSign Out

The site is intended for Australian healthcare professionals.


©2023 Pfizer Australia Pty Ltd. Sydney, Australia. All rights reserved.


PP-UNP-AUS-0551 12/23.

You are now leaving Pfizer
You are leaving PfizerPro.
You may be directed to a third-party website.
Please note third-party websites are not controlled by Pfizer or subject to our privacy policy.
PP-UNP-AUS-0551 12/23.
You are now leaving PfizerPro
​​​​​​​You are now leaving Links to external websites are provided as a resource to the viewer. This website is neither owned nor controlled by Pfizer Ltd. 

Pfizer accepts no responsibility for the content or services of the linked site other than the information or other materials relating to ​​​​​Pfizer medicines or 
business which it has provided or reviewed.

PP-PFE-GBR-3859. November 2021